Modality.AI

Upcoming webinar. Please join us!

You're invited! Our March webinar with Anna Yang, PharmD and Isaac R. Rodriguez-Chavez, PhD, MHSc, MSc., authors of Fundamentals of Decentralized Clinical Trials. https://lnkd.in/gaPfT48C Recently published by Springer, this handbook lays the groundwork for advancing and scaling decentralized clinical trials (DCTs). ?? Date: Wednesday, March 26, 2025 ?? Time: 10.00 AM Pacific / 1.00 PM Eastern Please join us! #clinicaltrials #clinicalresearch

If you're attending ISCTM be sure to connect our CEO David "DSO" Suendermann-Oeft and Senior Research Scientist Hardik Kothare, PhD during the conference or in the poster session where they'll showcase our recent work in ALS: “Predicting Disease Progression Trajectories in Individuals with Amyotrophic Lateral Sclerosis using Multimodal Digital Biomarkers.” #clinicaltrials #clinicalresearch #als #AmyotrophicLateralSclerosis

Our CSO Vikram Ramanarayanan was a co-presenter in the "Voice-based AI for Medicine: Practices for Ethical Interventions at Scale” session at the Annual Meeting of the American Association for the Advancement of Science (AAAS). Special thanks to Shelley Brundage and Nan Bernstein Ratner for steering the collaboration between The American Speech-Language-Hearing Association (ASHA) and AAAS. Pictured left to right: Session organizer and moderator Shelley Brundage, Professor, Speech, Language, and Hearing Sciences at George Washington University with co-presenters Vikram Ramanarayanan; Mark Hasegawa-Johnson, Professor at University of Illinois; and Visar Berisha, Associate Dean of Research Commercialization - College of Engineering at Arizona State University. #clinicaltrials #clinicalresearch

Advancing ALS Research: This week, Amy Easton, Senior Director of Scientific Programs at Target ALS, joined us to discuss direct-to-participant ALS research. A full recording of the conversation is available now. In this call we discussed: * The Innovation Ecosystem model developed by Target ALS to foster scientific collaboration between academia and biopharma * The role of self-directed assessments in improving diversity, retention, and sensitivity * Data sharing via the Target ALS Data Engine #clinicalresearch #clinicaltrials #ALS #amyotrophiclateralsclerosis https://lnkd.in/gvGTekvE

Attending ISCTM? Modality’s CEO David "DSO" Suendermann-Oeft and Senior Research Scientist Hardik Kothare, PhD will present a poster “Predicting Disease Progression Trajectories in Individuals with Amyotrophic Lateral Sclerosis using Multimodal Digital Biomarkers.” The International Society for CNS Clinical Trials and Methodology (ISCTM) is a multi-disciplinary independent organization devoted to promoting advances that address strategic clinical, regulatory, methodological and policy challenges that arise in the development and use of CNS therapeutic agents. This work is accomplished through partnership with persons in academia, industry, government, policy-making, and the public.? The organisation's 21st Annual Scientific Meeting takes place February 19-21 in Washington, DC. https://lnkd.in/eQnmGbZ #clinicaltrials #clinicalresearch #als #AmyotrophicLateralSclerosis

This week Modality.AI’s Chief Science Officer Vikram Ramanarayanan is presenting at the 2025 Annual Meeting of the American Association for the Advancement of Science (AAAS) in Boston. Vikram’s presentation is titled “Voice-based AI for Medicine: Practices for Ethical Interventions at Scale” https://lnkd.in/gfMwMgaz. This year's meeting theme is "Science Shaping Tomorrow," which emphasizes the pivotal role of scientific and technical expertise in public discourse and policymaking. *Voice-based AI for Medicine: Practices for Ethical Interventions at Scale* People with neurological and mental health disorders face health disparities and barriers in access to health care, jobs, and education. There is an urgent need for objective and remote clinical assessments for early diagnosis and monitoring of disease progression, and for user interfaces that can be used successfully by people with these disorders. Voice analytics and speech recognition are potential technological solutions to bridge health disparities and overcome barriers for people experiencing these disorders. Speakers will present real-world applications of voice analysis technologies across different health conditions, such as cerebral palsy, ALS, Parkinson's disease, and schizophrenia. Community-based speech technology has enabled highly accurate screening and user interface development at an unprecedented scale, resulting in expanded access to services, education, and employment. At the same time, communities that are excluded from technology training datasets cannot benefit from this work, exacerbating inequality. Finally, speakers will discuss associated ethical considerations, and advocate for a sociotechnical approach to AI model design, recognizing that building trustworthy and responsible clinical AI models is not strictly a technical problem. Ethical AI deployment requires ensuring access for all, including accurate understanding of speech patterns in people with disabilities, while safeguarding data privacy, security, and provenance. #clinicaltrials #clinicalresearch

You're Invited! We're pleased to share Amy Easton, Senior Director of Scientific Programs at Target ALS will join us on Feb 14 to discuss direct-to-participant ALS research. Register: https://lnkd.in/gK6xVqgx ???????? Date: Friday: February 14, 2025 ???????? Time: 11.30 AM Pacific / 2.30 PM Eastern In collaboration with Modality.AI, Target ALS has launched a pioneering Global Natural History Study that leverages our AI-driven audiovisual assessment platform to track ALS progression remotely. The study will recruit participants across the US and international sites, including Spanish-speaking countries, where enrollment has already begun. In this webinar we’ll discuss: * The Innovation Ecosystem model developed by Target ALS to foster scientific collaboration between academia and biopharma?? * The role of?audiovisual capture of?self-directed?assessments in improving diversity, retention, and sensitivity?of functional biomarkers of disease progression in ALS patients * Data sharing via the Target ALS Data Engine Join us to learn how this collaboration is moving ALS research forward. ?????? Register Here: https://lnkd.in/gK6xVqgx We look forward to your participation! About Target ALS Target ALS is a medical research foundation breaking down barriers to Amyotrophic Lateral Sclerosis (ALS) research to find effective treatments. Since 2013, Target ALS has revolutionized ALS research through its Innovation Ecosystem. By democratizing research through an unbiased review process, providing access to cutting-edge research tools, facilitating cross-disciplinary collaboration, and galvanizing industry involvement, Target ALS accelerates the most promising ideas in scientific research into drug development programs. Driven by impatient optimism, deliberate disruption, and radical collaboration, Target ALS aims to transform ALS into a manageable disease, building a world where Everyone Lives. #ALS #clinicaltrials #clinicalresearch

Discover the critical role of research in understanding and combating ALS at our upcoming "Importance of ALS Research” Webinar with Chicanos Por La Causa, Inc. (CPLC) on February 5th, 2025, from 5:30–7:00 PM MST. This unique event will highlight the collaborative efforts of Barrow Neurological Institute and Target ALS, with a special focus on ALS research in Phoenix and its impact on the Hispanic community, an often-underrepresented group in medical research. The evening’s agenda will feature expert speakers from both organizations, addressing a range of important topics: Judith Chavira (Barrow Neurological Institute) will welcome attendees and share insights into ALS outreach initiatives for the Hispanic community in Arizona. Dr. Shafeeq Ladha (Barrow Neurological Institute) will provide an overview of the Barrow Gregory W. Fulton ALS & Neuromuscular Disease Center and its history of advancing care for ALS patients. Dr. Robert P. Bowser, Ph.D. (Barrow Neurological Institute) will discuss the purpose and goals of ALS research, the benefits of participation, and how programs like our ALS Global Research Initiative (AGRI) are driving innovation. Dr. Amy Easton (Target ALS) will introduce Target ALS and highlight its mission to accelerate ALS research by breaking down barriers. Laura D. (Target ALS) will inform attendees about the power of research participation and how it has the potential to change lives. A live Q&A session led by Judith Chavira will provide the opportunity to engage directly with our panel of experts. You can join this educational event either in person or virtually: In-Person Attendance Central Park Recreational Center 140 E. Tonto St., Phoenix, AZ 85004 Virtual Attendance Join via Zoom: https://bit.ly/4glHI6G RSVP Today: Email: [email protected] Online: https://bit.ly/4gmFVy9 This event is a unique opportunity to learn from leading experts at Barrow Neurological Institute and Target ALS, connect with the community, and discover how you can contribute to advancing ALS research. #ALS #ALSResearch #Phoenix #AZ #Arizona

Modality CEO Dr. David Suendermann-Oeft and CSO Dr. Vikram Ramanarayanan present at the Als Network Research Summit: "Multimodal Speech Biomarkers for Remote Monitoring of ALS Disease Progression in Clinical Trials". https://lnkd.in/dRmWwFBd #als #clinicalresearch #clinicaltrials